---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-252544"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2026-06-02T12:00:36+00:00"
generated_at: "2026-06-02T12:05:11.428887+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA approves Afrezza for pediatric diabetes patients ages 6+

## Summary
- FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
- More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.
- Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.
- MannKind expects to expand the patient population for Afrezza beyond adults.

## SEC filing metadata
- accession: 0001193125-26-252544
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2026-06-02T12:00:36+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/0001193125-26-252544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/mnkd-20260529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-252544
- JSON: https://secwatch.observer/filing/0001193125-26-252544.json
- Plain text: https://secwatch.observer/filing/0001193125-26-252544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.